{"entity":{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","aka":[],"tldr":"Lung cancer pioneer whose IPASS trial established EGFR-targeted therapy as first-line treatment; chairs Clinical Oncology at CUHK.","summary":"Tony Mok is Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, practising at Prince of Wales Hospital. He led the IPASS trial, which showed that EGFR mutation status predicts benefit from gefitinib over chemotherapy, a landmark in the shift to biomarker-driven lung cancer treatment, and has led numerous subsequent global trials of targeted therapy and immunotherapy in lung cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mok+TS%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","precision oncology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["prince-of-wales-hospital-cuhk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman, Department of Clinical Oncology; Li Shu Fan Professor of Clinical Oncology","institutionId":"prince-of-wales-hospital-cuhk","specialisms":["Lung cancer","EGFR-targeted therapy","Precision oncology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mok+TS%5BAuthor%5D"}],"papers":[{"title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","journal":"New England Journal of Medicine","year":2009,"url":"https://doi.org/10.1056/NEJMoa0810699","doi":"10.1056/NEJMoa0810699"}]},"route":"/people/tony-mok/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"institution":[{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/"}],"paper":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/"},{"id":"paper-keynote-042-tmb-mutations-ann-oncol-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042","route":"/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/"},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/"},{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/"},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/"},{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/"}],"trial":[{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/"},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/"}]}}